

PACKAGE INSERT

hovid

FINAB CREAM 1% w/w

VIFIN03-VAR

Description

White to almost white homogenous cream free from grittiness.

Composition

Terbinafine hydrochloride 1% w/w

Actions and Pharmacology

Terbinafine is an allylamine which has a broad spectrum of antifungal activity in fungal infections of the skin. Its action being fungicidal against dermatophytes, moulds and certain dimorphous fungi. It has a fungicidal or fungistatic action on yeasts depending on the species involved. Terbinafine interferes with fungal ergosterol biosynthesis at an early stage. This leads to a deficiency in ergosterol and to intracellular accumulation of squalene, resulting in fungal cell death.

Terbinafine acts by inhibiting squalene epoxidase in the fungal cell membrane. The squalene epoxidase is not dependent on the cytochrome P450 system. Terbinafine does not have any influence on the metabolism of hormones or of other medicines.

Pharmacokinetics

Less than 5% of the dose is absorbed after topical application in humans; systemic exposure is thus very slight. Biotransformation results in metabolites with no antifungal activity, which is excreted predominantly in the urine and the faeces. The elimination half life is 17 hours. There is no evidence of accumulation. At the level of the stratum corneum, fungicidal concentrations of terbinafine can be measured up to 7 days after the last administration.

Indications

For the topical treatment of:

- Fungal infections of the skin caused by Trichophyton (e.g. *T. Rubrum*, *T. Mentagrophytes*, *T. Verrucosum*, *T. Violaceum*), *Microsporum canis* and *Epidermophyton floccosum*.
- Yeast infection of the skin, principally those caused by the genus *Candida* (e.g. *C. albicans*).
- Pityriasis (tinea) versicolor due to *Pityrosporum orbiculare* (also known as *Malassezia furfur*).

Contraindications

Hypersensitivity to terbinafine or to one of the adjuvants contained in the cream.

Warnings and Precautions

- For external use only.
- Contact with the eyes should be avoided. In case of accidental contact with the eyes, rinse the eyes thoroughly with running water.
- In the event of skin lesions, use with care if the preparation contains alcohol which can irritate.

Effects on Ability to Drive and Use Machines

Unlikely to impair a patient's ability to drive or use machinery.

Pregnancy and Lactation

There is no clinical experience in pregnant women; therefore, unless the potential benefits outweigh any potential risks, it should not be administered during pregnancy.

Terbinafine is excreted in breast milk and although the amount involved is small, mothers should not receive it whilst breast-feeding. Infants should also not be allowed to come into contact with any treated skin, including the breast.

Interaction with Other Medicaments

None known.

Main Side/Adverse Effects

Erythema (redness), pruritus (itching) or stinging (burning sensation) occasionally occurs at the site of application; however, treatment rarely has to be discontinued for this reason.

This must be distinguished from allergic reactions which are very rare but require discontinuation.

Overdose and Treatment

No case of overdose has been reported so far. However, should a large amount of the preparation be inadvertently ingested, adverse effects similar to those observed with an overdose of a tablet form of terbinafine are to be expected. These include headache, nausea, vomiting, epigastric pain and dizziness.

In case of accidental oral ingestion, gastric lavage and / or symptomatic supportive treatment should be performed as soon as possible.

Dosage and Administration

Adults and children from 12 years:

Cleanse and dry the affected areas thoroughly before application.

Apply a thin layer on the affected skin and surrounding areas by rubbing in gently.

Cream can be applied once or twice daily. The likely durations of treatment are as follows:

Tinea corporis, cruris: 1 to 2 weeks

Tinea pedis: Toes, twice daily for 1 week, on the bottom or sides of the foot for 2 weeks

Cutaneous candidiasis: 2 weeks

Pityriasis versicolor: 2 weeks

In cases of intertriginous infections (submammary, interdigital, intergluteal, inguinal), a gauze can be used, especially for applications in the evening.

Relief of clinical symptoms usually occurs within a few days. Regular application is essential for successful treatment. Irregular use or premature discontinuation of treatment carries the risk of recurrence. If there are no signs of improvement after one week, the diagnosis should be verified.

Children

The experience with topical terbinafine in children is still limited and its use cannot therefore be recommended.

Use in the elderly

There is no evidence to suggest that elderly patients require different dosages or experience side-effects different to those of younger patients.

Note : The information given here is limited. For further information consult your doctor or pharmacist.

Storage : Store below 30C. Protect from freezing.

Presentation/Packing : Cream 15g and 30g

Product Registration Holder/ Manufactured by: **HOVID Bhd.**, 121, Jalan Tunku Abdul Rahman (Jalan Kuala Kangsar), 30010, Ipoh, Perak, Malaysia.

Revision date: November 2018

2

9

5